# Use of electroconvulsive therapy (ECT) in new-onset refractory status epilepticus (NORSE): a case report and systematic review - URL: https://alisanburak.com/en/wcp-2026-posterler/so269 - Language: en - Last updated: not specified - Page title: Use of electroconvulsive therapy (ECT) in new-onset refractory status epilepticus (NORSE): a case report and systematic review | WCP 2026 Summary > All seven NORSE cases treated with ECT responded, with seizure remission achieved in 71% and no serious adverse effects reported. This page was translated automatically from Turkish. [Read the original](https://alisanburak.com/wcp-2026-posterler/so269) This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it. SO269 Brief Oral Poster PresentationNeuromodulationCase report and systematic review # Use of electroconvulsive therapy (ECT) in new-onset refractory status epilepticus (NORSE): a case report and systematic review THE USE OF ELECTROCONVULSIVE THERAPY (ECT) IN THE NEW ONSET REFRACTORY STATUS EPILEPTICUS (NORSE)—CASE REPORT AND SYSTEMATIC REVIEW Presenter: Savitha Puttaiah Country: United States of America Session: 3650 - PARALLEL SHORT ORAL POSTER SESSIONS: CONSULTATION LIAISON - Part II Date: Fri, 25.09.2026 All seven NORSE cases treated with ECT responded, with seizure remission achieved in 71% and no serious adverse effects reported. The aim was to evaluate the efficacy, safety, and outcomes of electroconvulsive therapy (ECT) in new-onset refractory status epilepticus (NORSE), a condition unresponsive to standard antiseizure treatments and associated with high morbidity and mortality. A PRISMA-compliant search of PubMed, EMBASE, and SCOPUS was conducted in June 2024; of the 1,039 records screened, 5 studies comprising 6 cases met the eligibility criteria, and a total of 7 cases were analyzed, including the institution's own case. The mean age was 37.1 years, and 57% were female; the mean interval from admission to the first ECT session was 37 days, and the mean number of ECT sessions was 9.7. Seizure remission was observed in 71% of cases and partial improvement in 29%; all seven cases responded (5 with remission and 2 with partial improvement), and no serious adverse effects were reported. The abstract also reported neuroimaging abnormalities in 71% of cases, cerebrospinal fluid abnormalities in 40%, use of a mean of 7 antiseizure medications before ECT, and cognitive impairment in 42%. The institution's case was a 30-year-old man with generalized tonic-clonic seizures refractory to five antiseizure medications, who tested positive for anti-GAD65 antibodies after discharge. Following the failure of midazolam, ketamine, pentobarbital, corticosteroids, plasmapheresis, IVIG, rituximab, and a ketogenic diet, he received 12 sessions of bitemporal ECT over 12 days using the Maryland protocol; remission was achieved at 2 months, and he was discharged to rehabilitation. The authors concluded that ECT may be an option as a rescue treatment for NORSE when standard interventions are insufficient, and that the apparent association between fewer sessions and better outcomes supports early ECT. However, they noted that the evidence was small-scale and retrospective, and that prospective studies were needed. [View the original poster](https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1559) How to cite this study APA 7: Puttaiah, S., et al. (2026, September 25). The use of electroconvulsive therapy (ect) in the new onset refractory status epilepticus (norse)—case report and systematic review [Poster presentation]. 26th WPA World Congress of Psychiatry (WCP 2026), Stockholm, Sweden. https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1559 Vancouver: Puttaiah S, et al. The use of electroconvulsive therapy (ect) in the new onset refractory status epilepticus (norse)—case report and systematic review [poster]. 26th WPA World Congress of Psychiatry (WCP 2026); 2026 Sep 23-26; Stockholm, Sweden. Available from: https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1559 Author names and title formatting were generated automatically from the congress system; please check them against the original poster before use. ## On the same topic - [Kumar oynama bozukluğunda teta patlama uyarımının klinik etkinliği ve plasebo etkileri: başlangıçtaki anksiyete ve depresyonun rolü](https://alisanburak.com/en/wcp-2026-posterler/ev0055) - [Transkraniyal darbe uyarımı (TPS) Alzheimer hastalığı olan hastalarda uygun bir ek tedavi mi?](https://alisanburak.com/en/wcp-2026-posterler/ev0407) - [Demansta tedaviye dirençli ajitasyonda elektrokonvulsif tedavi: anlatısal derleme](https://alisanburak.com/en/wcp-2026-posterler/ev0414) - [Elektrokonvulsif tedavi sonrası bilişsel değişimin nöroimmün ve psikolojik mekanizmaları: boylamsal MITO-ECT çalışmasının ön sonuçları](https://alisanburak.com/en/wcp-2026-posterler/ev0825) - [Yetişkin tedaviye dirençli depresyon hastalarında DEHB belirtilerini iyileştiren güçlendirilmiş tDCS'nin klinik ve görüntüleme mekanizmaları](https://alisanburak.com/en/wcp-2026-posterler/ev0851) [All WCP 2026 summaries](https://alisanburak.com/en/wcp-2026-posterler) --- Kaynak / Source: https://alisanburak.com/en/wcp-2026-posterler/so269 İletişim / Contact: Bağdat Caddesi, Veli Güneysu Apt. No:453 K:4 D:9, Suadiye / Kadıköy, İstanbul · +90 532 642 95 25 · info@alisanburak.com · https://alisanburak.com/bagdat-caddesi-psikoterapi-iletisim